You are here:

Clarithromycin 125 mg, 187.5 mg, 250 mg granules for oral suspension (ClaroSip®)

Advice

Following an abbreviated submission

Clarithromycin as Clarosip granules for oral suspension is not recommended for use within NHS Scotland for the treatment of acute and chronic infections caused by clarithromycin susceptible organisms.

It uses sip technology, where the granules are contained within a drinking straw. Clarosip incurs a cost premium of up to 20% compared to alternative oral liquid clarithromycin, with no proven advantage in terms of compliance

Drug Details

Drug Name: Clarithromycin 125 mg, 187.5 mg, 250 mg granules for oral suspension (ClaroSip®)
SMC Drug ID: 217/05
Manufacturer: Grünenthal Ltd
Indication: Acute and chronic infections caused by clarithromycin susceptible organisms
BNF Category:
Submission Type: Abbreviated Submission
Status: Not Recommended
Date Advice Published: 13 February 2006

Back